<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737448</url>
  </required_header>
  <id_info>
    <org_study_id>MP-0614-001</org_study_id>
    <nct_id>NCT03737448</nct_id>
  </id_info>
  <brief_title>TRimetazidine for acUte on Chronic Liver Failure STudy</brief_title>
  <acronym>TRUST</acronym>
  <official_title>A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the pharmacokinetics (PK), tolerability, and safety of oral&#xD;
      trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the PK, tolerability, and safety of oral trimetazidine administered to&#xD;
      subjects with acute-on-chronic (ACLF) Grades 1 and 2 with liver failure and a range of renal&#xD;
      function. Subjects will receive up to 60 mg/day for 28 days.&#xD;
&#xD;
      Two groups of subjects will be enrolled:&#xD;
&#xD;
      Group 1&#xD;
&#xD;
        -  AD with serum creatinine ≥ 1 and &lt; 2 mg/dL, OR&#xD;
&#xD;
        -  ACLF 1 with&#xD;
&#xD;
             -  liver failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or&#xD;
&#xD;
             -  liver failure and West Haven grade 1-2 hepatic encephalopathy, or&#xD;
&#xD;
             -  coagulation failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or&#xD;
&#xD;
             -  coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR&#xD;
&#xD;
        -  ACLF 2 with&#xD;
&#xD;
             -  liver failure and coagulation failure, or&#xD;
&#xD;
             -  liver failure and West Haven grade 3-4 hepatic encephalopathy.&#xD;
&#xD;
      Group 2&#xD;
&#xD;
        -  ACLF 1 with renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), OR&#xD;
&#xD;
        -  ACLF 2 with&#xD;
&#xD;
             -  liver failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), or&#xD;
&#xD;
             -  coagulation failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Lack of enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma pharmacokinetics</measure>
    <time_frame>28 days</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma pharmacokinetics</measure>
    <time_frame>28 days</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD with serum creatinine ≥ 1 and &lt; 2 mg/dL, OR&#xD;
ACLF 1 with&#xD;
liver failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or&#xD;
liver failure and West Haven grade 1-2 hepatic encephalopathy, or&#xD;
coagulation failure and serum creatinine ≥ 1.5 and &lt; 2 mg/dl, or&#xD;
coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR&#xD;
ACLF 2 with&#xD;
liver failure and coagulation failure, or&#xD;
liver failure and West Haven grade 3-4 hepatic encephalopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACLF 1 with renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), OR&#xD;
ACLF 2 with&#xD;
liver failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL), or&#xD;
coagulation failure and renal failure (serum creatinine ≥ 2.0 and &lt; 3.5 mg/dL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <description>Subjects with receive up to 60 mg daily</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years, inclusive, at screening.&#xD;
&#xD;
          2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as&#xD;
             determined at the discretion of the investigator)*.&#xD;
&#xD;
          3. Anticipated duration of hospital stay of at least 7 days.&#xD;
&#xD;
          4. For Group 1:&#xD;
&#xD;
               -  AD with SCr ≥ 1 and &lt; 2 mg/dL, OR&#xD;
&#xD;
               -  ACLF 1 with&#xD;
&#xD;
                    -  Tbil ≥ 12 mg/dL, SCr ≥ 1.5 and &lt; 2 mg/dl, and HE 0-2, or&#xD;
&#xD;
                    -  Tbil ≥ 12 mg/dL, and SCr &lt; 1.5 mg/dL, and HE 1-2, or&#xD;
&#xD;
                    -  INR ≥ 2.5, SCr ≥ 1.5 and &lt; 2 mg/dl, and HE 0-2, or&#xD;
&#xD;
                    -  INR ≥ 2.5, SCr &lt; 1.5 mg/dL, and HE 1-2, OR&#xD;
&#xD;
               -  ACLF 2 with&#xD;
&#xD;
                    -  Tbil ≥ 12 mg/dL, INR ≥ 2.5, and SCr &lt; 2 mg/dL, or&#xD;
&#xD;
                    -  Tbil ≥ 12 mg/dL, HE 3-4, and SCr &lt; 2 mg/dL&#xD;
&#xD;
          5. For Group 2:&#xD;
&#xD;
               -  ACLF 1 with SCr ≥ 2.0 and &lt; 3.5 mg/dL, OR&#xD;
&#xD;
               -  ACLF 2 with&#xD;
&#xD;
                    -  Tbil ≥ 12 mg/dL, and SCr ≥ 2 and &lt; 3.5 mg/dL, or&#xD;
&#xD;
                    -  INR ≥ 2.5, and SCr ≥ 2 and &lt; 3.5 mg/dL.&#xD;
&#xD;
          6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree&#xD;
             to sexual abstinence or use a highly effective method of contraception from Screening&#xD;
             to 3 days after the final dose.&#xD;
&#xD;
          7. Non sterile male patients must agree to sexual abstinence or use a highly effective&#xD;
             method of contraception from Screening to 3 days after the final dose if sexually&#xD;
             active.&#xD;
&#xD;
          8. Able to comprehend and willing to sign an informed consent form, or, if unable to&#xD;
             consent, consent is conducted per local requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of AD or ACLF (of any grade) &gt;14 days before enrollment*.&#xD;
&#xD;
          2. Circulatory failure.&#xD;
&#xD;
          3. Respiratory failure i.e. PaO2/FiO2 ≤ 200 and/or baseline SpO2/FiO2 ≤ 214.&#xD;
&#xD;
          4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation&#xD;
             failure (INR &gt; 2.5).&#xD;
&#xD;
          5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this&#xD;
             criterion may qualify after 72 hours).&#xD;
&#xD;
          6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial&#xD;
             peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at&#xD;
             the discretion of the investigator).&#xD;
&#xD;
          7. Invasive fungal infection.&#xD;
&#xD;
          8. Platelet count &lt;30,000 cells/mL.&#xD;
&#xD;
          9. White blood cell count &lt;1000 cells/uL.&#xD;
&#xD;
         10. Patients on hemodialysis or continuous venovenous hemofiltration.&#xD;
&#xD;
         11. Patients who have undergone or are scheduled for imminent organ transplantation.&#xD;
             (Patients may be on a transplant list as long as no date has been set for&#xD;
             transplantation)&#xD;
&#xD;
         12. Hospitalization for ACLF within the 3 months prior to screening.&#xD;
&#xD;
         13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions&#xD;
             each &lt; 3 cm or 1 lesion &lt; 5 cm; no extrahepatic involvement; no evidence of gross&#xD;
             vascular invasion).&#xD;
&#xD;
         14. Active non-hepatic malignancy.&#xD;
&#xD;
         15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.),&#xD;
             restless leg syndrome or other movement disorders other than asterixis.&#xD;
&#xD;
         16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome.&#xD;
&#xD;
         17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure&#xD;
             of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (&gt; 18&#xD;
             mg/dL) after adequate fluid resuscitation.&#xD;
&#xD;
         18. Patients who have undergone placement of a transjugular intrahepatic portosystemic&#xD;
             shunt (TIPS) or surgical shunt in the past 6 months.&#xD;
&#xD;
         19. Any invasive procedure within 48 hours prior to enrollment with high risk of&#xD;
             uncontrolled bleeding (as determined at the discretion of the investigator).&#xD;
&#xD;
         20. Female with a positive pregnancy test or lactating.&#xD;
&#xD;
         21. Positive results for human immunodeficiency virus HIV-1 or HIV-2.&#xD;
&#xD;
         22. Current treatment with trimetazidine.&#xD;
&#xD;
         23. Known allergy to trimetazidine or excipients.&#xD;
&#xD;
         24. Currently receiving an investigational treatment.&#xD;
&#xD;
         25. Any condition that, in the opinion of the Investigator (or designee), would limit the&#xD;
             subject's ability to complete or participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Martin Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JW Goethe Clinic</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

